MedPath

Fluticasone furoate

Generic Name
Fluticasone furoate
Brand Names
Arnuity Ellipta, Avamys, Breo Ellipta, Flonase Sensimist, Trelegy Ellipta, Veramyst
Drug Type
Small Molecule
Chemical Formula
C27H29F3O6S
CAS Number
397864-44-7
Unique Ingredient Identifier
JS86977WNV
Background

Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications. Fluticasone furoate was first approved in 2007.

Indication

Fluticasone furoate is indicated for once-daily maintenance (i.e. prophylactic) treatment of asthma in patients ≥5 years old. Fluticasone furoate is available in two combination medications - one in combination with vilanterol and one in combination with both vilanterol and umeclidinium- which are both indicated for the management of chronic obstructive pulmonary disease (COPD) and for the treatment of asthma in patients ≥18 years old for the vilanterol-umeclidinium-fluticasone product and ≥5 years old for the vilanterol-fluticasone product.

Fluticasone furoate is available over the counter as a nasal spray for the symptomatic treatment of hay fever and other upper respiratory allergies in patients ≥2 years old.

Associated Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergy, Seasonal Allergies
Associated Therapies
-
Clinical Trials
Related News

Rhinitis, Cognition and Driving Performance

Not Applicable
Completed
Conditions
Driving Ability
Cognition
Seasonal Allergic Rhinitis
Interventions
Drug: cetirizine 10 mg
Drug: fluticasone furoate
Drug: placebo
First Posted Date
2011-03-18
Last Posted Date
2013-11-08
Lead Sponsor
Maastricht University Medical Center
Target Recruit Count
22
Registration Number
NCT01318681
Locations
🇳🇱

Maastricht University, Maastricht, Limburg, Netherlands

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Phase 3
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: fluticasone furoate
Drug: fluticasone furoate/vilanterol
Drug: vilanterol
Other: Placebo
First Posted Date
2011-03-14
Last Posted Date
2018-08-06
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
16568
Registration Number
NCT01313676
Locations
🇻🇳

GSK Investigational Site, Hue, Vietnam

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects

Phase 1
Completed
Conditions
Asthma
Interventions
Drug: fluticasone furoate//GW642444
Drug: GW642444
Drug: fluticasone furoate
First Posted Date
2011-02-18
Last Posted Date
2017-06-12
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
16
Registration Number
NCT01299558
Locations
🇦🇺

GSK Investigational Site, Randwick, New South Wales, Australia

A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

Completed
Conditions
Rhinitis, Allergic, Perennial
Interventions
Drug: mometasone furoate
Drug: Fluticasone furoate
Drug: fluticasone propionate
First Posted Date
2010-09-13
Last Posted Date
2017-08-14
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
540
Registration Number
NCT01199757

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Placebo
Drug: Fluticasone propionate
Drug: Fluticasone furoate
First Posted Date
2010-07-12
Last Posted Date
2017-11-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
350
Registration Number
NCT01159912
Locations
🇷🇴

GSK Investigational Site, Iasi, Romania

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: Fluticasone Furoate
Drug: FF/GW642444M
Drug: GW642444M
Drug: Placebo
First Posted Date
2010-05-24
Last Posted Date
2017-01-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
27
Registration Number
NCT01128595
Locations
🇸🇪

GSK Investigational Site, Lund, Sweden

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: FF/Vilanterol (VI; GW642444M)
Drug: Placebo
Drug: Fluticasone Furoate
First Posted Date
2010-05-24
Last Posted Date
2017-01-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
52
Registration Number
NCT01128569
Locations
🇬🇧

GSK Investigational Site, Manchester, United Kingdom

Asthma Exacerbation Study

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Fluticasone Furoate/GW642444
Drug: Fluticasone furoate
First Posted Date
2010-03-15
Last Posted Date
2018-01-24
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
2020
Registration Number
NCT01086384
Locations
🇺🇦

GSK Investigational Site, Zaporizhia, Ukraine

Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease

Phase 4
Terminated
Conditions
Patients With Nasal Polyps
Interventions
Other: placebo
Drug: fluticasone furoate
First Posted Date
2009-11-16
Last Posted Date
2017-09-13
Lead Sponsor
Johns Hopkins University
Target Recruit Count
7
Registration Number
NCT01013701

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects

Phase 1
Completed
Conditions
Asthma
Interventions
Drug: fluticasone furoate
First Posted Date
2009-10-23
Last Posted Date
2017-06-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
80
Registration Number
NCT01000597
Locations
🇦🇺

GSK Investigational Site, Randwick, New South Wales, Australia

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy